AstraZeneca sells Atacand rights to Cheplapharm for $400m

30th Oct 2020 07:23

(Sharecast News) - AstraZeneca said it was selling the commercial rights to its heart failure and hypertension drug Atacand and Atacand Plus in around 70 countries globally to Cheplapharm Arzneimittel for $400m.
The deal is expected to complete in the final quarter of 2020, AstraZeneca said on Friday, adding that $250m of the purchase price would be payable on completion and the rest in the first half of 2021.

.

Top Risers

Share	Price	Change
CAP-XX (CPX)	0.445	50.85%
Westmount Engy. (WTE)	1.675	45.65%
Ukrproduct (UKR)	6.50	23.81%
Ethernity Net (ENET)	0.0215	22.86%
Red Rock Resources (RRR)	0.03	20%

Top Fallers

Share	Price	Change
Synthomer (SYNT)	64.80	-17.77%
Dominos (DOM)	209.00	-15.04%
Genincode (GENI)	1.75	-11.62%
Karelian (KDR)	0.575	-11.54%
polarean (POLX)	0.975	-11.36%

Top By Volume

Share	Price	Volume
Caledonian Hold (CHP)	0.003	688,555,703
CAP-XX (CPX)	0.445	513,547,225
Rockfire Resources (ROCK)	0.125	348,216,529
Premier African Minerals (PREM)	0.03	324,231,022
Ethernity Net (ENET)	0.0215	256,663,922

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.